Purin-6-One Derivatives as Phosphodiesterase-2 Inhibitors

Yuan, Wei; Zhao, Xin-Yun; Chen, Xi; Zhan, Chang-Guo

doi:https://doi.org/10.1155/2016/6878353

Journal of Chemistry

On this page

Abstract Introduction Results and Discussion Conclusions Acknowledgments Supplementary Materials References Copyright Related Articles

Research Article | Open Access

Volume 2016 | Article ID 6878353 | https://doi.org/10.1155/2016/6878353

Purin-6-One Derivatives as Phosphodiesterase-2 Inhibitors

Wei Yuan,¹Xin-Yun Zhao,¹Xi Chen,¹and Chang-Guo Zhan²

Academic Editor: José L. A. Mediano

Received12 Dec 2015

Revised14 Jan 2016

Accepted17 Jan 2016

Published22 Feb 2016

Abstract

A series of purin-6-one derivatives were synthesized, and their in vitro inhibitory activity against phosphodiesterase-2 (PDE2) was evaluated by using a fluorescence polarization assay. Three compounds, that are, 2j, 2p, and 2q, showed significant inhibitory activity against PDE2 with IC₅₀ values of 1.73, 0.18, and 3.43 μM, respectively. Structure-activity relationship (SAR) analysis was performed to explore the relationship between the chemical structures of these compounds and their inhibitory activity. Compounds 2j, 2p, and 2q were further selected for molecular docking study. The docking results suggested that these ligands bind with hydrophobic pockets of the catalytic active site of PDE2, where a Tyr655 residue was found to be important in binding with compound 2p, the most potent inhibitor identified in this study. Our present study provides useful information for the future design of novel PDE2 inhibitors.

1. Introduction

Mammalian cyclic nucleotide phosphodiesterases (PDEs) could catalyze the hydrolysis of ubiquitous intracellular second messengers cyclic adenosine monophosphate (cAMP) and/or cyclic guanosine monophosphate (cGMP) into inactive 5′-AMP and/or 5′-GMP to modulate a number of physiological processes. Numerous studies have proved that PDEs were excellent drug targets for the development of therapeutic agents against various diseases [1, 2]. The human genome encodes 11 PDE families (PDE1 to PDE11) to produce a series of PDE isoenzymes [3–5]. There is only one gene coding for PDE2, namely, PDE2A. PDE2A has been described to degrade both substrates cAMP and cGMP. Its enzymatic activity can be allosterically activated by cGMP. Additionally, PDE2A is preferentially expressed in the mammalian heart [6] and brain tissues [7]. Animal behavioral models have indicated that PDE2 inhibition plays a key role in the control of memory and anxiety [8–10]. It could also be considered as a promising therapeutic target for cognition enhancement in Alzheimer’s disease [11].

Among the as-reported PDE2 selective inhibitors, there are four inhibitors particularly interesting to many scientists. As shown in Figure 1, EHNA was the first reported PDE2 inhibitor with IC₅₀ value of 1 μM [12]. BAY 60-7550 and PDP (Figure 1) exhibited excellent inhibitory activities against PDE2A with IC₅₀ values of 4.7 and 0.6 nM, respectively [8, 13]. ND7001 was under development by Neuro 3D and advanced into clinical phase I in 2005, showing potent inhibitory activity against PDE2 [14] with IC₅₀ value of 57 nM. However, according to the reports of Thomson Reuters Pharma, developments of BAY 60-7550 and ND7001 were ceased due to their poor pharmacokinetics performances [15].

Despite various X-ray crystal structures for PDE2 having been reported [16, 17], the shape of the binding pocket of PDE2 remained uncertain until 2013, when Huang et al. have reported the X-ray crystal structure of PDE2A complexed with BAY 60-7550 [18]. The crystal structure revealed that this compound binds to the PDE2 active site using not only the conserved glutamine-switch mechanism for substrate binding but also a binding induced hydrophobic pocket, which is lined by Leu770, His773, Thr805, Leu809, Ile866, and Ile870 (Figure 2). It has never been reported before. The binding mode of BAY 60-7550 with the active site of PDE2 in crystal state is depicted in Figure 2. As shown in this figure, the –NH-CO– moiety of BAY 60-7550 forms bidentate hydrogen bonding to the invariant glutamine (Gln859) and the imidazotriazin-4-one core stack against the side chain of Phe862 and Phe830. In addition, the phenyl ring is filled into the binding induced hydrophobic pocket, which significantly contributes to the binding of BAY 60-7550 with PDE2.

Inspired by the information mentioned in Figure 2, a series of purin-6-one derivatives were designed and synthesized by keeping the core scaffolds purin-6-one and changing the substituents at 2- and 9-positions on the purin-6-one. Fluorescence polarization assay was performed to test the inhibitory effect in vitro using recombinant human PDE2 in the presence of 10 μM of inhibitors. For those compounds with higher inhibitory activity, IC₅₀ values against PDE2 were also determined. Ligand-protein docking studies were performed to investigate the binding modes of these purin-6-one derivatives with the PDE2 catalytic domain. Our present studies provide useful information for the design of novel PDE2 inhibitors.

2. Results and Discussion

2.1. Chemistry

All compounds synthesized in this study have been summarized in Table 1. The general synthetic routes of these target compounds are depicted in Scheme 1. The key intermediates 5-amino-1-substituted-imidazole-4-carboxamides 1(1a, 1c, 1d, 1i, 1n, and 1p) were firstly synthesized (Scheme 1) using amines, 2-amino-2-cyanoacetamide, and triethyl orthoformate as raw materials. Their synthetic route was modified from the work of Banerjee et al. [19] by adding pyridine as catalyst under the refluxing conditions. The yield of 1a (R = CH₂CH₂OH) was higher (73.2%) than that reported (42%) in the work of Banerjee et al. The melting point and ¹H NMR of 1c (R = CH₂C₆H₅) were found to be consistent with those reported by Shaw and Alhede [20, 21]. Compounds 1n and 1p were synthesized by using 3-amino-4-phenyl-butan-2-ol and 3-amino-6-phenyl-hexan-2-ol as starting materials. Target compounds were synthesized by refluxing intermediates 1 and the corresponding esters in the presence of sodium methoxide. Purin-6-one derivative 2c was then reacted with allyl bromide to give N1-alkylated (2c-1) and O6-alkylated (2c-2) products in the presence of NaH. Compounds 2n and 2o were further oxidized to 2r and 2s under DMSO using SO₃/pyridine complex [22]. Their structures were confirmed by ¹H NMR, ¹³C NMR, IR, and mass spectroscopy. The single-crystal structure of compound 2a was also determined by our X-ray crystallography [23].

2.2. Inhibitory Activity of Purin-6-One Derivatives against PDE2 and SAR Studies

The in vitro inhibitory activity against the recombinant human PDE2 was evaluated for final compounds by using fluorescence polarization assay. The inhibition ratios of target compounds against PDE2 in the presence of 10 μM of inhibitor were summarized in Table 1. Results from Table 1 indicated that varying substituent at the 2- and 9-position will lead to remarkably different inhibitory activities. Keeping R = −CH₂CH₂OH, replacing R¹ (3-methoxybenzyl) in compound 2a with 3,4-dimethoxybenzyl (compound 2b) will increase inhibitory ratio from 48% (2a) to 78% (2b). When R and R¹ were, respectively, to be –CH₂C₆H₅ and 2-methylbenzyl (compound 2c), the inhibitory ratio value decreased to 35%. It was postulated that large nonpolar groups at R substituent will be unfavorable for PDE2A inhibition. This assumption is further confirmed by the inhibitory values (18–42%) of compounds 2d and 2f–2h, R groups of which were nonpolar group −(CH₂)₃C₆H₅. The only exception is compound 2e; the inhibitory ratio is 78%, which is the same as the inhibitory value of 2b. Increasing the chain length of R in compound 2e to –(CH₂)₄C₆H₅ leads to compound 2i, which has an inhibitory activity essentially identical to that of 2e. Further adding a methoxyl group to 3-position of phenyl ring of R¹ in 2i results in compound 2j, which has a significant stronger inhibitory activity with a value of 95%. In contrast, adding a methyl group to the 2-position of phenyl ring of R¹ in 2i (compound 2k) leads to a much less potent inhibitory with a value of only 24%. The difference of R¹ groups and inhibitory values between 2j and 2k clearly demonstrates that adding a moderately nonpolar group at the 3- or 5-position of benzyl at R¹-position is favorable.

Based on the discussion above, we further compare the structure of 2b and 2d. It could be found that the presence of a hydroxyl (e.g., –CH₂CH₂OH) in R group is more favorable than a nonpolar R substituent (e.g., –(CH₂)₃C₆H₅) without a hydroxyl. In addition, comparing the inhibition ratio of 2d (44%) to that of 2j (95%), one can find that the bulkiness of R group should also be important to the PDE2A inhibition. Combining these two points, we tried to introduce a bulky –(CH₃)CH(OH) group to the existing R group of 2i. The resulting compound, that is, 2p, shows excellent inhibitory activities with inhibition ratio of 100%. However, when the –(CH₃CHOH)CH(CH₂)₃C₆H₅ group of compound 2p was replaced with a less bulky group, that is, –(CH₃CHOH)CHCH₂C₆H₅ (compound 2n), the corresponding inhibition ratio drops to 73%. Hence, the presence of hydroxyl and bulky size of R group are both important for inhibition activity.

Beltman et al. have reported a series of cGMP analogues and evaluated the inhibitory activities of these compounds against PDE2. The N1-methylated cGMP analogues generally exhibited weak inhibitory activity, as compared to those cGMP analogues with a hydrogen on N1. SAR study suggested that N1-methylation of cGMP analogues will result in the loss of a hydrogen bond or increase the steric hindrance with the binding pocket of PDE2, which will lead to reduced inhibitory activities [24]. This study concerns the importance of maintaining bidentate hydrogen bonds formed between the γ-amide of Gln859 and the carbonyl O6, NH moiety of the inhibitors. To testify this idea, we also synthesized N1-allylated derivative of compound 2c, namely, 2c-1. Interestingly, we observed a remarkably improved inhibitory activity of compound 2c-1 (N1-allylation), which is contrary to Beltman’s reports. As can be seen from Table 1, the inhibitory ratio of 2c-1 is higher (57%) than that (35%) of 2c. Although 2c-1 loses a hydrogen donor at its N1-position because of the allylation at this place, the loss of the hydrogen bonding interaction can be compensated by the hydrophobic interaction formed between the allyl group and the surrounding hydrophobic pocket of PDE2. Hence, for purine-6-one derivatives it is not necessary to form a bidentate hydrogen bond between the N1-H and γ-amide of Gln859 to maintain optimal PDE2 inhibitory activity. On the other hand, when the O6-position of 2c is attached with an allyl group, the resulting compound 2c-2 shows a much weaker inhibitory activity (9%), as compared to that (35%) for 2c. Our present study shows that the carbonyl oxygen at 6-position of purin-6-one scaffold (the scaffold consists of atoms 1 to 9. See Table 1 for numbering of these atoms) probably plays a key role in binding with PDE2.

The values in Table 1 show that compounds 2j, 2p, and 2q have potent inhibitory activities. These three compounds were then selected for further inhibitory activity tests at various concentrations in order to calculate IC₅₀ value, which showed a submicromolar inhibitory activity.

2.3. Molecular Modeling

The results from the preliminary activities prompted us to pay attention to three of the more potent compounds (2j, 2p, and 2q) with higher inhibitory activity against PDE2. In an effort to gain an understanding of the structural basis for the empirical structure-activity relationships observed, we further studied the binding mode of the compounds (2j, 2p, and 2q) through molecular docking. For this purpose, the crystal structure of PDE2 in complex with BAY 60-7550 (PDB ID: 4HTX) was selected as the receptor for molecular docking. Before docking, the complex-ligand and water molecules were removed from the complex structure, except for four water molecules and a hydroxide ion that bound with the metal ions Zn²⁺ and Mg²⁺ at the catalytic pocket. Then hydrogen atoms were added by using the Leap tools implemented in AMBER software. The molecular structures of 2j, 2p, and 2q were constructed by GaussView followed by geometrical optimization at PM3 level. For the receptor and each ligand, the nonpolar hydrogen atoms were merged and Gasteiger charges were added. Then AUTODOCK4.2 program was used to search for the most favorable binding mode of the ligands and PDE2 catalytic domain. During the docking process, atoms in the receptor were kept constant. 100 docking runs were performed for each ligand and the conformations with the lowest binding free energies were selected for analysis.

Molecular docking revealed that all of these inhibitors bind with PDE2 in a similar binding mode (Figure 3). From this figure, it could be found that each of the PDE2 inhibitors was fitted in a cavity formed by Phe830, Phe862, Ile826, Gln859, Met845, Met847, Leu770, His773, Leu809, Ile866, and Ile870 residues. In the PDE2-ligand binding complexes (Figure 3), the common purin-6-one scaffold of the inhibitors is lodged in the hydrophobic pocket surrounded by the side chains of Ile826, Ile866, Phe830, and Phe862 residues, causing a high degree of surface complementarities. Hydrogen bonds were formed between the purin-6-one and the γ-amide of Gln859. In addition, R groups of ligands were clapped by the hydrophobic H pocket formed by His773, Leu809, Ile866, and Ile870 residues, which was also observed in the crystal structure of PDE2 in complex with BAY 60-7550. R¹ group of the inhibitors formed additional hydrophobic interaction with the peripheral residues Met847, Leu858, and Ile866.

(a)

(b)

(c)

In addition to the common features mentioned above, the hydroxyl group of R¹ substituent of inhibitor 2p forms an extra hydrogen bonding interaction with the side chain of Tyr655 (see Figure 3(b)), which will enhance the binding of 2p with PDE2. Compared to the binding mode of 2p, 2j (Figure 2(a)) and 2q (Figure 2(c)) do not interact with Tyr655, implying that their binding affinities with PDE2 will be weaker than that of 2p. As can be seen from Table 2, the binding free energies () predicted by AUTODOCK are consistent with the corresponding experimental binding free energies (), suggesting that the present binding modes of these compounds are reliable.

It is worth noting that the interaction with Tyr655 has never been reported before. Hence, this residue can be considered as a new site for the development of novel PDE2 inhibitors. Compound 2p can be regarded as a good starting structure for the design of new PDE2 inhibitors.

3. Conclusions

A series of purin-6-one derivatives were designed and synthesized as potential PDE2 inhibitors. SAR studies suggested that the carbonyl oxygen at 6-position of purin-6-one derivatives played a key role in maintaining the inhibitory activity against PDE2 enzyme. Three more potential compounds 2j, 2p, and 2q were identified to have submicromolar IC₅₀ values. Molecular docking of compounds 2j, 2p, and 2q into the catalytic domain of the PDE2 revealed a similar binding profile with PDE2 to that of BAY 60-7550. Residue Tyr655, which has been never reported before, was found to be potential binding target for PDE2 inhibitors. The binding mode analysis indicates that optimization of 2p compound is promising to be a leading structure for the design of novel PDE2 inhibitors.

4. Experimental Section

4.1. Chemistry

¹H NMR spectra were recorded on a Varian NMR 600 MHz instrument or Mercury plus 400 MHz, and the chemical shifts, δ, are in ppm and tetramethylsilane as internal standard. Graphical ¹H NMR spectra of the compounds 2b–2s in this work are collected in the Supplementary Material available online at http://dx.doi.org/10.1155/2016/6878353. Mass spectra were determined using Trace MS 2000 organic mass spectrometry, and signals are given in m/z. Melting points were recorded on Büchi B-545 melting point apparatus. Elemental analysis (EA) was carried out with a Vario EL III CHNSO elemental analyzer. Conventional heating was carried out on Corning stirrer/hotplates with oil baths. Thin layer chromatography (TLC) inspections were carried out on a silica gel GF₂₅₄ plates. Triethyl orthoformate, 2-cyano-2-amino-acetamide, and other chemical reagents otherwise noted were commercially available. Solvents were dried in a routine way and redistilled. Esters were prepared using acid as raw materials in the presence of acetyl chloride and alcohol.

4.1.1. General Procedures for Synthesis of the Intermediate 5-Amino-4-carboxamide-1-substituted-1H-imidazole (1)

20 mmol of 2-amino-2-cyanoacetamide was suspended in 30 mL absolute acetonitrile, and 23 mmol of triethyl orthoformate and 0.03 g pyridine as a catalyst were added to the suspension with stirring. The suspension was heated to reflux temperature using an oil bath preheated to 100°C and the suspension was held at boiling temperature for 1 h and then 20 mmol of substituted amine was then added over a 3 to 5 min period and boiling was continued for an additional 15 min. The reaction was quickly cooled to room temperature and then solvent was evaporated, and the residue was recrystallized from DMF-ethanol to give the product.

(1) 5-Amino-1-(2-hydroxyethyl)-1H-imidazole-4-carboxamide (1a). M.p.: 142.6°C, Yield: 73.2%. ¹H NMR (400 MHz, DMSO-d₆): δ, 7.06 (s, 1H, CH), 6.72, 6.58 (pair of s, br, 2H, CONH₂), 5.68 (s, 2H, ArNH₂), 5.03 (s, 1H, OH), 3.83 (t, 2H, Hz, CH₂O), 3.61 (t, 2H, Hz, CH₂N). EI-MS: m/z (relative intensity) 170.9 (M+1, 55), 169.8 (97), 125.8 (91), 109.8 (74), 108.7 (100), 44.8 (67).

(2) 5-Amino-1-benzyl-1H-imidazole-4-carboxamide (1c). M.p.: 250.8°C, Yield: 76%. ¹H NMR (600 MHz, DMSO-d₆): δ, 7.19–7.37 (m, 6H, ArH+CH), 6.64, 6.79 (pair of s, 2H, CONH₂), 5.84 (s, 2H, ArNH₂), 5.07 (s, 2H, ArCH₂). EI-MS: m/z (relative intensity) 216.2 (M⁺, 23), 91.2 (100), 65.1 (26), 44.3 (7).

(3) 5-Amino-1-(3-phenylpropyl)-1H-imidazole-4-carboxamide (1d). M.p.: 198.1°C, Yield: 76%. ¹H NMR (600 MHz, DMSO-d₆): δ, 7.17–7.30 (m, 5H, ArH), 7.11 (s, 1H, CH), 6.61, 6.76 (pair of s, 2H, CONH₂), 5.80 (s, 2H, NH₂), 3.82 (t, CH₂, Hz), 2.50–2.58 (m, 2H, CH₂), 1.91–1.99 (m, 2H, CH₂). EI-MS: m/z (relative intensity): 244.2 (M, 44), 210.3 (26), 140.1 (61), 123.1 (82), 117.1 (42), 109 (33), 91.1 (100), 77.0 (18), 65.0 (25), 44.2 (14).

(4) 5-Amino-1-(4-phenylbutyl)-1H-imidazole-4-carboxamide (1i). M.p.: 222°C, Yield: 72%. ¹H NMR (600 MHz, DMSO-d₆): δ, 7.14–7.27 (m, 5H, ArH), 7.07 (s, 1H, CH), 6.57, 6.70 (pair of s, 2H, CONH₂), 5.76 (s, 2H, NH₂), 3.80 (t, CH₂, Hz), 2.58 (t, CH₂, Hz), 1.62–1.66 (m, 2H, CH₂), 1.49–1.54 (m, 2H, CH₂). EI-MS: m/z (relative intensity) 258.5 (M⁺, 51), 224.2 (22), 213.8 (9), 154.1 (13), 149.9 (22), 137.2 (12), 126.1 (17), 108.9 (28), 91.1 (100), 76.9 (14), 65.0 (26).

(5) 5-Amino-1-[1-(1-hydroxyethyl)-2-phenylethyl]-1H-imidazole-4-carboxamide (1n). M.p.: 231.4°C, Yield: 67%. ¹H NMR (600 MHz, DMSO-d₆): δ, 7.12–7.23 (m, 6H, ArH), 6.56, 6.69 (pair of s, 2H, CONH₂), 5.60 (s, 2H, NH₂), 5.31 (d, 1H, OH, Hz), 4.18–4.22 (m, 1H, CH), 3.90–3.93 (m, 1H, CH), 3.12–3.26 (m, 2H, CH₂), 1.05 (d, 3H, CH₃, Hz). EI-MS: m/z (relative intensity) 274.2 (M⁺, 5), 166 (2), 126 (17), 109 (15), 91.2 (100), 77.0 (17), 65.0 (27), 51.2 (12), 45.3 (60).

(6) 5-Amino-1-[1-(1-hydroxyethyl)-4-phenylbutyl]-1H-imidazole-4-carboxamide (1p). ¹H NMR (600 MHz, DMSO-d₆): δ, 7.12–7.26 (m, 6H, ArH+1H), 6.75, 6.60 (pair of s, 2H, CONH₂), 5.74 (s, 2H, NH₂), 5.13 (d, 1H, OH, Hz), 3.82–3.83 (m, 2H, CH+CH), 2.53–2.61 (m, 2H, CH₂), 1.80–1.91 (m, 2H, CH₂), 1.32–1.41 (m, 2H, CH₂), 0.95 (d, 3H, CH₃, Hz). EI-MS: m/z (relative intensity) 303.6 (M+1, 13), 302.2 (M⁺, 73), 268.1 (25), 240.4 (8), 256.9 (168), 152.9 (208), 126 (100), 108.9 (71), 91.1 (83), 77.0 (13), 65.1 (14), 55.2 (14), 43.1 (25).

4.1.2. General Procedure for the Preparation of Purin-6-One Derivatives (2a–2q)

1.4 mmol of 5-amino-1-substituted-4-carboxamide-1H-imidazole (1) was dissolved in 10 mL of absolute methanol. Then 5.6 mmol of the appropriate ester is added into this solution. This mixture was added in 10 mL of methoxide-methanol solution prepared from sodium (0.15 g, 6.3 mmol) and 10 mL of absolute methanol. The mixture was refluxed for 15–20 h. After cooling, the solvent was evaporated off and the residue was taken into ethyl acetate. The organic phase was dried over Na₂SO₄ and evaporated. And the residue was purified via silica gel chromatography (eluent: the mixture of ethyl acetate and methanol) to obtain the pure product (2a–2q).

(1) 9-(2-Hydroxy-ethyl)-2-(3-methoxy-benzyl)-1,9-dihydro-purin-6-one (2a). The data of ¹H NMR, IR, EI-MS, elemental analysis, and X-ray crystal was reported in our previous study [23].

(2) 2-(3,4-Dimethoxy-benzyl)-9-(2-hydroxy-ethyl)-1,9-dihydro-purin-6-one (2b). M.p.: 223.6°C, Yield: 76%. ¹H NMR (400 MHz, DMSO-d₆): δ, 12.27 (s, NH, 1H), 7.95 (s, CH, 1H), 7.02 (s, ArH, 1H), 6.86–6.93 (m, ArH, 2H), 4.97 (t, OH, 1H, Hz), 4.15 (t, CH₂, 2H, Hz), 3.86 (s, CH₂, 2H), 3.74–3.71 (8H, OCH₃+CH₂). ¹³C NMR (100 MHz, DMSO-d₆): δ, 157.8, 157.3, 149.4, 149.1, 148.3, 141.1, 129.4, 122.4, 121.2, 113.1, 112.3, 59.85, 56.03, 55.95, 55.9, 46.5. EI-MS: m/z (relative intensity) 330.0 (M⁺, 100), 299.1 (39), 285.1 (15), 271.0 (33), 239.0 (17), 151.1 (24), 135.1 (23), 109.1 (19), 91.1 (12), 77.1 (16), 65.2 (18), 51.2 (7), 45.2 (13). IR (cm⁻¹): 3327 (N-H), 3079, 2939, 1711 (C=O), 1583, 1516, 1439, 1408, 1262, 1237, 1162, 1067, 1058, 1020, 647. Anal. calcd for C₁₆H₁₈N₄O₄: C, 58.17; H, 5.49; N, 16.96. Found: C, 58.15; H, 5.82; N, 16.63.

(3) 9-Benzyl-2-(2-methyl-benzyl)-1,9-dihydro-purin-6-one (2c). The data of ¹H NMR, ¹³C NMR, IR, EI-MS, and elemental analysis was reported in our previous study [25].

(4) 2-(3,4-Dimethoxy-phenyl)-9-(3-phenyl-propyl)-1,9-dihydro-purin-6-one (2d). M.p.: 235.3°C, Yield: 45%. ¹H NMR (600 MHz, DMSO-d₆): δ, 12.33 (br, s, 1H, NH), 8.11 (s, 1H, CH), 7.75 (s, 1H, ArH), 7.80 (d, 1H, ArH, Hz), 7.18–7.29 (m, 5H, ArH), 7.11 (d, 1H, ArH, Hz), 4.21 (t, 2H, CH₂, Hz), 3.86 (s, 3H, OCH₃), 3.85 (s, 3H, OCH₃), 2.63 (t, 2H, CH₂, Hz), 2.17–2.22 (m, 2H, CH₂). ¹³C NMR (100 MHz, DMSO-d₆): δ, 158.0, 153.0, 151.92, 159.86, 149.4, 149.0, 148.9, 141.3, 141.0, 128.8, 126.4, 124.9, 121.6, 112.0, 111.3, 56.2, 56.1, 43.3, 32.6, 31.5. EI-MS: m/z (relative intensity) 390.2 (M⁺, 75), 363.5 (19), 285.0 (100), 269.1 (10), 198.9 (17), 164.2 (12), 148 (8), 117.2 (13), 104.2 (10), 91.1 (67), 77.2 (13), 65.0 (21), 51.3 (7). IR (cm⁻¹): 3431 (N-H), 3093, 3012, 2933, 1685 (C=O), 1559, 1539, 1514, 1304, 1269, 1223, 1178, 1024, 876, 754, 702. Anal. calcd for C₂₂H₂₂N₄O₃: C, 67.68; H, 5.68; N, 14.35. Found: C, 68.05; H, 5.38; N, 14.18.

(5) 2-Benzyl-9-(3-phenyl-propyl)-1,9-dihydro-purin-6-one (2e). M.p.: 225.1°C, Yield: 62%. ¹H NMR (600 MHz, DMSO-d₆): δ, 12.38 (s, 1H, NH), 8.04 (s, 1H, CH), 7.15–7.36 (m, 10H, ArH), 4.12 (t, 2H, CH₂, ), 3.96 (s, 2H, CH₂), 2.54 (t, 2H, CH₂, Hz), 2.08–2.13 (m, 2H, CH₂). ¹³C NMR (100 MHz, DMSO-d₆): δ, 157.8, 157.0, 149.3, 141.3, 140.6, 137.2, 129.2, 128.9, 128.8, 128.7, 127.3, 126.4, 122.6, 43.4, 39.4, 32.5, 31.4. EI-MS: m/z (relative intensity) 344.3 (M⁺, 2), 239.2 (22), 183.1 (6), 117.2 (10), 91.1 (100), 77.2 (22), 65.2 (24), 51.2 (15), 44.2 (29). IR (cm⁻¹): 3442 (N-H), 3097, 2940, 2864, 1724 (C=O), 1581, 1494, 1453, 1410, 1361, 1128, 718, 698, 654. Anal. calcd for C₂₁H₂₀N₄O: C, 73.23; H, 5.85; N, 16.27. Found: C, 73.59; H, 6.10; N, 16.62.

(6) 2-(2-Methyl-benzyl)-9-(3-phenyl-propyl)-1,9-dihydro-purin-6-one (2f). M.p.: 214.2°C, Yield: 57%. ¹H NMR (600 MHz, DMSO-d₆): δ, 12.33 (s, 1H, NH), 8.03 (s, 1H, CH), 7.11–7.26 (m, 9H, ArH), 4.06 (t, 2H, CH₂, Hz), 3.97 (s, 2H, CH₂), 2.50 (t, 2H, CH₂, Hz), 2.34 (s, 3H, CH₃), 2.04–2.07 (m, 2H, CH₂). ¹³C NMR (100 MHz, DMSO-d₆): δ, 157.8, 156.9, 149.3, 141.2, 140.59, 140.57, 137.0, 135.7, 130.5, 129.5, 128.8, 128.6, 127.3, 126.4, 122.6, 43.5, 38.2, 32.5, 31.3, 19.9. EI-MS: m/z (relative intensity) 358.3 (M⁺, 35), 343.2 (20), 253.3 (100), 254.4 (40), 240.3 (16), 228.3 (16), 105.3 (15), 91.2 (52). IR (cm⁻¹): 3433 (N-H), 3069, 3026, 2948, 2867, 1718 (C=O), 1582, 1493, 1454, 1410, 1364, 1157, 1125, 756, 695, 651. Anal. calcd for C₂₂H₂₂N₄O: C, 73.72; H, 6.19; N, 15.63. Found: C, 74.09; H, 6.25; N, 15.98.

(7) 2-(4-Chloro-phenyl)-9-(3-phenyl-propyl)-1,9-dihydro-purin-6-one (2g). M.p.: 248.4°C, Yield: 42%. ¹H NMR (600 MHz, DMSO-d₆): δ, 12.53 (s, 1H, NH), 8.16 (s, 1H, CH), 8.13 (d, 2H, Hz), 7.62 (d, 2H, Hz), 7.18–7.29 (m, 5H, ArH), 4.22 (t, 2H, CH₂, Hz), 2.62 (t, 2H, CH₂, Hz), 2.17–2.20 (m, 2H, CH₂). EI-MS: m/z (relative intensity) 364 (M⁺, 23), 343.5 (15), 277.5 (17), 259.0 (100), 240.5 (16), 225.5 (20), 199.4 (12), 118.6 (26), 103.5 (18), 91.0 (43), 77.1 (12), 65.1 (13), 44.3 (21). IR (cm⁻¹): 3433 (N-H), 3097, 2940, 2860, 1705 (C=O), 1549, 1493, 1452, 1411, 1364, 1128, 1090, 1008, 846, 787, 755, 698, 682. Anal. calcd for C₂₀H₁₇ClN₄O: C, 65.84; H, 4.70; N, 15.36. Found: C, 66.17; H, 5.04; N, 15.03.

(8) 2-(2,4-Dichloro-phenoxymethyl)-9-(3-phenyl-propyl)-1,9-dihydro-purin-6-one (2h). M.p.: 188.2°C, Yield: 66%. ¹H NMR (600 MHz, DMSO-d₆): δ, 12.51 (s, 1H, NH), 8.11 (s, 1H, CH), 7.58 (s, 1H, ArH), 7.13–7.34 (m, 7H, ArH), 5.14 (s, 2H, CH₂), 4.11 (t, 2H, CH₂, Hz), 2.50 (t, 2H, CH₂, Hz), 2.03–2.05 (m, 2H, CH₂). EI-MS: m/z (relative intensity) 430.4 (M+1, 7), 429.5 (M⁺, 7), 428.0 (18), 393.1 (10), 344.5 (6), 277.3 (18), 268.5 (33), 266.9 (70), 240.2 (17), 198.6 (8), 182.9 (8), 164.2 (72), 161.8 (100), 125.9 (12), 98.0 (15), 91.1 (28), 62.6 (21). IR (cm⁻¹): 3441 (N-H), 3098, 3027, 2939, 2811, 1718 (C=O), 1600, 1532, 1482, 1456, 1412, 1301, 818, 753, 699, 504. Anal. calcd for C₂₁H₁₈Cl₂N₄O₂: C, 58.75; H, 4.23; N, 13.05. Found: C, 58.39; H, 4.11; N, 13.12.

(9) 2-Benzyl-9-(4-phenyl-butyl)-1,9-dihydro-purin-6-one (2i). M.p.: 197.3°C, Yield: 73%. ¹H NMR (600 MHz, DMSO-d₆): δ, 12.38 (s, 1H, NH), 8.04 (s, 1H, CH), 7.13–7.33 (m, 10H, ArH), 4.12 (t, 2H, CH₂, Hz), 3.94 (s, 2H, CH₂), 2.56 (t, 2H, CH₂, Hz), 1.76–1.81 (m, 2H, CH₂), 1.46–1.51 (m, 2H, CH₂). EI-MS: m/z (relative intensity) 358.1 (M⁺, 55.51), 330.1 (28.66), 267.2 (8.26), 253.1 (20.71), 239.1 (26.38), 225.3 (45.65), 213 (9.66), 109.0 (15.93), 91.1 (100.00), 77.0 (10.93), 65.0 (17.75), 55.2 (7.37), 45.2 (14.01). IR (cm⁻¹): 3427 (N-H), 3103, 3061, 2936, 2860, 1723 (C=O), 1578, 1454, 1412, 1373, 1357, 1127, 944, 748, 698, 658. Anal. calcd for C₂₂H₂₂N₄O: C, 73.72; H, 6.19; N, 15.63. Found: C, 73.79; H, 6.14; N, 15.93.

(10) 2-(3-Methoxy-benzyl)-9-(4-phenyl-butyl)-1,9-dihydro-purin-6-one (2j). M.p.: 177.3°C, Yield: 41%. ¹H NMR (600 MHz, DMSO-d₆): δ, 12.34 (s, 1H, NH), 8.03 (s, 1H, CH), 7.12–7.26 (m, 6H, ArH), 6.95 (s, 1H, ArH), 6.88 (d, 1H, ArH, Hz), 6.81 (d, 1H, ArH, Hz), 4.13 (t, 2H, CH₂, Hz), 3.91 (s, 2H, CH₂), 3.71 (s, 3H, OCH₃), 2.56 (t, 2H, CH₂, Hz), 1.78–1.80 (m, 2H, CH₂), 1.48–1.51 (m, 2H, CH₂). ¹³C NMR (100 MHz, DMSO-d₆) δ 159.7, 157.8, 156.9, 149.3, 142.2, 140.6, 138.5, 130.0, 128.7, 128.7, 126.2, 122.5, 121.3, 115.1, 112.6, 55.4, 43.3, 40.7, 34.8, 29.5, 28.3. EI-MS: m/z (relative intensity) 388.2 (M⁺, 59), 342.9 (22), 283.9 (32), 269.0 (35), 255.2 (74), 239.5 (23), 225.8 (60), 212.4 (23), 182.8 (33), 160.8 (28), 147.3 (29), 131.2 (37), 109.0 (38), 102.8 (39), 90.6 (100), 76.6 (28), 44.3 (27). IR (cm⁻¹): 3433 (N-H), 3085, 2938, 1673 (C=O), 1582, 1453, 1379, 1257, 1146, 1049, 747, 700. Anal. calcd for C₂₃H₂₄N₄O₂: C, 71.11; H, 6.23; N, 14.42. Found: C, 71.39; H, 6.20; N, 14.78.

(11) 2-(2-Methyl-benzyl)-9-(4-phenyl-butyl)-1,9-dihydro-purin-6-one (2k). M.p.: 219.4°C, Yield: 62%. ¹H NMR (600 MHz, DMSO-d₆): δ, 12.31 (s, 1H, NH), 8.02 (s, 1H, CH), 7.10–7.25 (m, 9H, ArH), 4.06 (t, 2H, CH₂, Hz), 3.96 (s, 2H, CH₂), 2.32 (s, 3H, CH₃), 1.73–1.75 (m, 2H, CH₂), 1.42–1.45 (m, 2H, CH₂). EI-MS: m/z (relative intensity) 372.3 (M⁺, 12.41), 344.3 (19.98), 253.3 (14.56), 240.3 (100.00), 224.3 (14.22), 91.2 (29.45), 76.4 (7.32). IR (cm⁻¹): 3440 (N-H), 3102, 3026, 2942, 2860, 1723 (C=O), 1582, 1559, 1493, 1452, 1410, 1364, 1159, 1123, 759, 696, 652. Anal. calcd for C₂₃H₂₄N₄O: C, 74.17; H, 6.49; N, 15.04. Found: C, 74.21; H, 6.45; N, 15.34.

(12) 2-(2,4-Dichloro-phenoxymethyl)-9-(4-phenyl-butyl)-1,9-dihydro-purin-6-one (2l). M.p.: 208.6°C, Yield: 72%. ¹H NMR (600 MHz, DMSO-d₆): δ, 12.51 (s, 1H, NH), 8.09 (s, 1H, CH), 7.60 (s, 1H, ArH), 7.36 (d, 1H, ArH, Hz), 7.12–7.25 (m, 6H, ArH), 5.14 (s, 2H, CH₂), 4.10 (t, 2H, CH₂, Hz), 2.50–2.53 (2H, CH₂), 1.69–1.72 (m, 2H, CH₂), 1.40–1.44 (m, 2H, CH₂). EI-MS: m/z (relative intensity) 443.6 (M⁺, 71), 442.3 (51), 372.4 (29), 369.2 (40), 356.4 (99), 328.8 (54), 296.2 (28), 256.1 (100), 239.0 (44), 211.8 (70), 160.8 (39), 103.2 (72), 91.2 (37), 77.3 (59), 76.2 (74), 51.3 (24), 43.2 (36). IR (cm⁻¹): 3437 (N-H), 3098, 3028, 2932, 2862, 1718 (C=O), 1602, 1481, 1456, 1411, 1234, 820, 720, 699, 651, 506. Anal. calcd for C₂₂H₂₀Cl₂N₄O₂: C, 59.60; H, 4.55; N, 12.64. Found: C, 59.31; H, 4.23; N, 12.31.

(13) 2-(4-Chloro-phenyl)-9-(4-phenyl-butyl)-1,9-dihydro-purin-6-one (2m). M.p.: 228.1°C, Yield: 30%. ¹H NMR (600 MHz, DMSO-d₆): δ, 12.52 (s, 1H, NH), 8.14 (s, 1H, CH), 8.11 (d, 2H, Hz), 7.61 (d, 2H, Hz), 7.14–7.24 (m, 5H, ArH), 4.23 (t, 2H, CH₂, Hz), 2.62 (t, 2H, CH₂, Hz), 1.85–1.87 (m, 2H, CH₂), 1.54–1.57 (m, 2H, CH₂). EI-MS: m/z (relative intensity) 379.3 (M+1, 24), 378.1 (M⁺, 49), 337.9 (30), 274.9 (14), 259.3 (38), 224.3 (3), 164.3 (13),109.3 (17), 91.1 (100). IR (cm⁻¹): 3435 (N-H) 3103, 3026, 2937, 2859, 1688 (C=O), 1600, 1549, 1494, 1454, 1411, 1367, 1090, 1011, 842, 787, 732, 699, 498, 472. Anal. calcd for C₂₁H₁₉ClN₄O: C, 66.58; H, 5.05; N, 14.79. Found: C, 66.28; H, 4.88; N, 14.46.

(14) 2-Benzyl-9-(1-benzyl-2-hydroxy-propyl)-1,9-dihydro-purin-6-one (2n). M.p.: 225.2°C, Yield: 66%. ¹H NMR (600 MHz, CDCl₃): δ, 12.49 (s, 1H, NH), 6.83–7.42 (m, 11H, ArH), 4.38–4.40 (m, 2H, CH₂), 4.13 (s, 2H, CH₂), 3.21–3.31 (m, 2H, CH₂), 1.39 (d, 3H, CH₃, Hz). EI-MS: m/z (relative intensity): 374.4 (M⁺, 22), 330.4 (27), 329.2 (24), 283.3 (7), 226.3 (83), 225.0 (57), 102.8 (21), 91.1 (100), 77.0 (17), 65.0 (22), 45.3 (18). IR (cm⁻¹): 3214, 1677 (C=O), 1591, 1455, 1374, 716, 691. Anal. calcd for C₂₂H₂₂N₄O₂: C, 70.57; H, 5.92; N, 14.96. Found: C, 70.39; H, 5.84; N, 14.77.

(15) 9-(1-Benzyl-2-hydroxy-propyl)-2-(2-methyl-benzyl)-1,9-dihydro-purin-6-one (2o). M.p.: 86.6°C, Yield: 88%. ¹H NMR (600 MHz, DMSO-d₆): δ, 12.24 (s, 1H, NH), 7.99 (s, 1H, CH), 6.88–7.21 (m, 10H, ArH), 4.42–4.45 (m, 1H, CH), 3.93–4.04 (m, 1H, CH), 3.91 (s, 2H, CH₂), 3.21–3.23 (m, 1H, CH), 2.32 (s, 3H, CH₃), 0.91 (d, 3H, CH₃, Hz). ¹³C NMR (100 MHz, DMSO-d₆): δ, 157.7, 156.5, 149.3, 140.1, 138.4, 136.99, 135.7, 130.5, 129.4, 128.9, 128.5, 127.3, 126.5, 126.3, 122.3, 68.4, 63.1, 38.1, 35.6, 20.7, 19.9. EI-MS: m/z (relative intensity) 388.3 (M⁺, 99), 342.6 (25), 240.3 (100), 223.4 (26), 212.3 (21), 131.3 (35), 91.1 (17), 76.8 (16), 42.9 (17). IR (cm⁻¹): 3389 (N-H), 3087, 2970, 1680 (C=O), 1586, 1495, 1456, 1408, 1372, 1154, 1124, 746, 701, 650. Anal. calcd for C₂₃H₂₄N₄O₂: C, 71.11; H, 6.23; N, 14.42. Found: C, 71.09; H, 6.50; N, 14.07.

(16) 2-Benzyl-9-[1-(1-hydroxy-ethyl)-4-phenyl-butyl]-1,9-dihydro-purin-6-one (2p). M.p.: 180.4°C, Yield: 78%. ¹H NMR (600 MHz, DMSO-d₆): δ, 12.38 (s, 1H, NH), 8.05 (s, 1H, CH), 7.02–7.33 (m, 10H, ArH), 5.14 (d, 1H, OH, Hz), 4.22–4.26 (m, 1H, CH), 3.94 (3H, CH₂+CH), 2.41–2.45 (m, 2H, CH₂), 2.00–2.06 (m, 2H, CH₂), 1.21–1.29 (m, 2H, CH₂), 0.87 (d, 3H, CH₃, Hz). IR (cm⁻¹): 3397 (N-H), 3085, 3026, 2934, 1666 (C=O), 1581, 1402, 1372, 749, 699. Anal. calcd for: C₂₄H₂₆N₄O₂: C, 71.62; H, 6.51; N, 13.92. Found: C, 71.39; H, 6.58; N, 14.04.

(17) 2-(4-Chloro-phenyl)-9-[1-(1-hydroxy-ethyl)-4-phenyl-butyl]-1,9-dihydro-purin-6-one (2q): The Mixture of Isomers (1 : 1). M.p.: 263.4°C, Yield: 39%. ¹H NMR (600 MHz, DMSO-d₆): δ, 12.54 (s, 1H, NH), 8.16 (s, 1H, CH), 8.11–8.13 (m, 3H, ArH), 8.07 (s, 1H, ArH), 7.61 (d, 4H, ArH), 5.15 (dd, 1H, OH, Hz), 4.35–4.45 (m, 1H, CH), 4.04–4.10 (m, 1H, CH), 2.51–2.63 (m, 2H, CH₂), 1.87–2.11 (m, 2H, CH₂), 1.29–1.41 (m, 2H, CH₂), 0.95 (d, 3H, CH₃, Hz). EI-MS: m/z (relative intensity) 423.0 (M⁺, 4), 246.9 (3), 138.1 (7), 104.2 (7), 91.1 (100), 77.2 (10), 65.0 (17), 51.2 (6), 45.1 (37). IR (cm⁻¹): 3436 (N-H), 3084, 2930, 1687 (C=O), 1599, 1548, 1492, 1367, 1089, 840, 699, 549. Anal. calcd for: C₂₃H₂₃ClN₄O₂: C, 65.32; H, 5.48; N, 13.25. Found: C, 65.66; H, 6.59; N, 13.58.

4.1.3. General Procedures of Synthesis of 2r and 2s

(1) 2-Benzyl-9-(1-benzyl-2-oxo-propyl)-1,9-dihydro-purin-6-one (2r). 15 mL of absolute dichloromethane and triethylamine (5.22 g, 6.39 mmol) was added to 2n (0.58 g, 1.55 mmol) and the mixture was cooled to 0°C using an ice-bath. 1.5 mL of DMSO and 3.26 g of pyridine/sulphur trioxide complex were added, and the mixture was then under an atmosphere of nitrogen, stirred in ice bath for 1 h, and heated at 60°C for further 6 h. 20 mL of water was added to the solution, and the mixture was extracted three times with in each case 25 mL of dichloromethane. The organic phases were washed with water and then dried over sodium sulfate and concentrated using a rotary evaporator. The crude product was purified by chromatography to give 0.43 g of title compound.

M.p.: 60°C, Yield: 74.7%. ¹H NMR (600 MHz, CDCl₃): δ, 12.84 (br, 1H, NH), 7.75 (s, 1H, CH), 6.96–7.38 (m, 10H, ArH), 5.40 (dd, 1H, CH, Hz, Hz), 4.07 (s, 2H, CH₂), 3.57 (dd, 1H, CH, Hz, Hz), 3.29 (dd, 1H, CH, Hz, Hz), 2.18 (s, 3H, CH₃). ¹³C NMR (100 MHz, CDCl₃): δ, 202.47, 159.49, 149.46, 157.5, 149.62, 139.1, 135.5, 135.3, 129.3, 128.9, 128.7, 127.4, 127.3, 122.1, 64.3, 41.3, 36.9, 28.0. EI-MS: m/z (relative intensity) 372.0 (M⁺, 16), 329.2 (100), 224.9 (38), 212.7 (8), 102.8 (33), 91.1 (79), 76.9 (19), 65.0 (21), 51.2 (7), 43.2 (43). IR (cm⁻¹): 3440 (N-H), 3087, 3029, 2922, 1684 (C=O), 1580, 1455, 1410, 717, 699. Anal. calcd for: C₂₂H₂₀N₄O₂: C, 70.95; H, 5.41; N, 15.04. Found: C, 70.76; H, 5.73; N, 14.56.

(2) 9-(1-Benzyl-2-oxo-propyl)-2-(2-methyl-benzyl)-1,9-dihydro-purin-6-one (2s). 2s was prepared by oxidating 2o using similar method to that of compound 2r.

M.p.: 209.0°C, Yield: 72%. ¹H NMR (600 MHz, CDCl₃): δ, 12.12 (s, 1H, NH), 7.72 (s, 1H, CH), 6.94–7.28 (m, 9H, ArH), 5.30 (dd, 1H, CH₂, Hz, Hz), 3.52 (dd, 1H, CH₂, Hz, Hz), 3.24 (dd, 1H, CH₂, Hz, Hz), 2.31 (s, 3H, CH₃), 2.10 (s, 3H, CH₃CO). EI-MS: m/z (relative intensity) 386.4 (M⁺, 8), 342.8 (17), 298.5 (13), 225.3 (30), 199.5 (9), 171.3 (12), 143.2 (19), 103.3 (35), 91.0 (100), 77.2 (10), 65.2 (12), 43.6 (8). ¹³C NMR (101 MHz, DMSO-d₆) δ 203.6, 157.6, 157.1, 149.2, 140.5, 137.0, 135.6, 130.5, 129.4, 129.0, 128.7, 127.3, 127.0, 126.3, 122.3, 64.9, 38.1, 35.1, 27.5, 19.9. IR (cm⁻¹): 3440 (N-H), 3081, 3025, 2905, 1731 (C=O), 1660, 1587, 1458, 1408, 1354, 1234, 1174, 748, 732, 655. Anal. calcd for: C₂₃H₂₂N₄O₂: C, 71.48; H, 5.74; N, 14.50. Found: C, 71.31; H, 6.09; N, 14.48.

4.1.4. The Procedure for Synthesis of 2c-1 and 2c-2 [26]

A mixture of 2c (0.22 g) and NaH (70%, 0.04 g) in 6 mL of dry DMF was stirred at room temperature for 0.5 h; then ally bromide (0.15 g) was added to this solution and stirred for 4.5 h at the same temperature. And ice-water (100 mL) was added to the solution with stirring; the solid deposited was filtered and washed with water. The two regioisomers cropped were separated by column chromatography on silica gel using the mixture of petroleum ether and EtOAc as eluting solvent to afford the corresponding 2c-1 (0.08 g) and 2c-2 (0.13 g) as the first and second fractions, respectively.

(1) 1-Allyl-9-benzyl-2-(2-methyl-benzyl)-1,9-dihydro-purin-6-one 2c-1. M.p.: 82°C, Yield: 33%. ¹H NMR (600 MHz, DMSO-d₆): δ, 8.21 (s, 1H, CH), 7.02–7.30 (m, 9H, ArH), 5.99–6.00 (m, 1H, CH₂), 5.09 (dd, 2H, CH₂, Hz, Hz), 5.08 (s, 2H, CH₂), 4.75–4.98 (m, 2H, CH₂), 4.20 (s, 3H, CH₃), 2.14 (s, 3H, CH₃). EI-MS: m/z (relative intensity) 370.1 (M⁺, 16), 355.0 (10), 278.9 (6), 265.3 (8), 238.2 (6), 171.1 (19), 105.0 (21), 91.3 (100), 76.8 (8), 65.0 (22), 44.2 (6). IR (cm⁻¹): 3442, 3085, 2945, 1689 (C=O), 1553, 1515, 1354, 1186, 750, 718. Anal. calcd for: C₂₃H₂₂N₄O: C, 74.57; H, 5.99; N, 15.12. Found: C, 73.91; H, 5.79; N, 15.39.

(2) 6-Allyloxy-9-benzyl-2-(2-methyl-benzyl)-9H-purine 2c-2. M.p.: 133.5°C, Yield: 53%. ¹H NMR (600 MHz, DMSO-d₆): δ, 8.44 (s, 1H, CH), 7.11–7.31 (m, 9H, ArH), 6.02–6.09 (m, 1H, CH), 5.39 (s, 2H, CH₂), 5.36 (d, 1H, CH, Hz), 5.24 (d, 1H, CH, Hz), 4.99 (d, 1H, CH₂), 4.17 (s, 2H, CH₂), 2.32 (s, 3H, CH₃). EI-MS: m/z (relative intensity) 370.2 (M⁺, 3), 128.8 (5), 105.1 (12), 91.1 (100), 89.3 (10), 65.1 (25), 55.2 (8), 44.1 (18). IR (cm⁻¹): 3417, 3077, 2944, 1597, 1574, 1445, 1410, 1375, 1245, 1065, 935, 741, 643. Anal. calcd for: Anal. calcd for: C₂₃H₂₂N₄O: C, 74.57; H, 5.99; N, 15.12. Found: C, 74.39; H, 5.53; N, 14.98.

4.2. Enzymatic Activities of Recombinant Human PDE2 Using an In Vitro Enzymatic Assay

The enzyme inhibitory activities of the synthesized compounds were evaluated against PDE2 using recombinant human PDE2 by BPS Bioscience Inc. (San Diego, California, USA) using fluorescence polarization method. Tested compounds were dissolved in DMSO and diluted in assay buffer (final DMSO concentration 1%, final inhibitor concentration 10 μM). PDE activity assays were performed in duplicate at each concentration. The reaction was conducted at room temperature for 60 minutes in a 50 μL mixture containing reaction buffer, 100 nM FAM-cAMP as substrate, 1 μM cGMP, recombinant human PDE2 (0.75 ng/reaction), and a tested compound. Fluorescence intensity was measured at an excitation of 485 nm and an emission of 528 nm using BioTek Synergy™ 2 microplate reader (San Diego, California, USA).

Fluorescence intensity was converted to fluorescence polarization using the Gen5 software. The fluorescence polarization data were analyzed using the computer software, GraphPad Prism (GraphPad Software Inc., San Diego, CA). The value of fluorescence polarization () from the reactions without the compound was defined as 100% activity. In the absence of PDE2 and the compound, the value of fluorescent polarization () was defined as 0% activity. The percent activity in the presence of the compound was calculated according to the following equation: activity% = ()/() × 100%. In the equation, FP is the fluorescence polarization in the presence of the compound.

Conflict of Interests

The authors declare that there is no conflict of interests regarding the publication of this paper.

Acknowledgments

The research was supported in part by National Institutes of Health (Grant RC1MH088480), National Natural Science Foundation of China (Grant 21273089), and the Special Fund for Basic Scientific Research of Central Colleges, South-Central University for Nationalities (CZY14004).

Supplementary Materials

The supplementary material provides the ¹H NMR (2b-2s) and ¹³C NMR (2b-2f) Spectra of target molecules.

Supplementary Material

References

M. J. Speakman, “PDE5 inhibitors in the treatment of LUTS,” Current Pharmaceutical Design, vol. 15, no. 30, pp. 3502–3505, 2009.
View at: Publisher Site | Google Scholar
Y.-J. Wang, Y.-L. Jiang, H.-F. Tang, C.-Z. Zhao, and J.-Q. Chen, “Zl-n-91, a selective phosphodiesterase 4 inhibitor, suppresses inflammatory response in a COPD-like rat model,” International Immunopharmacology, vol. 10, no. 2, pp. 252–258, 2010.
View at: Publisher Site | Google Scholar
A. T. Bender and J. A. Beavo, “Cyclic nucleotide phosphodiesterases: molecular regulation to clinical use,” Pharmacological Reviews, vol. 58, no. 3, pp. 488–520, 2006.
View at: Publisher Site | Google Scholar
C. Lugnier, “Cyclic nucleotide phosphodiesterase (PDE) superfamily: a new target for the development of specific therapeutic agents,” Pharmacology & Therapeutics, vol. 109, no. 3, pp. 366–398, 2006.
View at: Publisher Site | Google Scholar
K. Omori and J. Kotera, “Overview of PDEs and their regulation,” Circulation Research, vol. 100, no. 3, pp. 309–327, 2007.
View at: Publisher Site | Google Scholar
H. L. Trong, N. Beier, W. K. Sonnenburg et al., “Amino acid sequence of the cyclic GMP stimulated cyclic nucleotide phosphodiesterase from bovine heart,” Biochemistry, vol. 29, no. 44, pp. 10280–10288, 1990.
View at: Publisher Site | Google Scholar
E. Reyes-Irisarri, M. Markerink-Van Ittersum, G. Mengod, and J. De Vente, “Expression of the cGMP-specific phosphodiesterases 2 and 9 in normal and Alzheimer's disease human brains,” The European Journal of Neuroscience, vol. 25, no. 11, pp. 3332–3338, 2007.
View at: Publisher Site | Google Scholar
F. G. Boess, M. Hendrix, F.-J. van der Staay et al., “Inhibition of phosphodiesterase 2 increases neuronal cGMP, synaptic plasticity and memory performance,” Neuropharmacology, vol. 47, no. 7, pp. 1081–1092, 2004.
View at: Publisher Site | Google Scholar
K. Domek-Łopacińska and J. B. Strosznajder, “The effect of selective inhibition of cyclic GMP hydrolyzing phosphodiesterases 2 and 5 on learning and memory processes and nitric oxide synthase activity in brain during aging,” Brain Research, vol. 1216, pp. 68–77, 2008.
View at: Publisher Site | Google Scholar
A. Masood, Y. Huang, H. Hajjhussein et al., “Anxiolytic effects of phosphodiesterase-2 inhibitors associated with increased cGMP signaling,” Journal of Pharmacology and Experimental Therapeutics, vol. 331, no. 2, pp. 690–699, 2009.
View at: Publisher Site | Google Scholar
A. S. R. Sierksma, K. Rutten, S. Sydlik et al., “Chronic phosphodiesterase type 2 inhibition improves memory in the APPswe/PS1dE9 mouse model of Alzheimer's disease,” Neuropharmacology, vol. 64, pp. 124–136, 2013.
View at: Publisher Site | Google Scholar
T. Podzuweit, P. Nennstiel, and A. Müller, “Isozyme selective inhibition of cGMP-stimulated cyclic nucleotide phosphodiesterases by erythro-9-(2-hydroxy-3-nonyl) adenine,” Cellular Signalling, vol. 7, no. 7, pp. 733–738, 1995.
View at: Publisher Site | Google Scholar
J. Seybold, D. Thomas, M. Witzenrath et al., “Tumor necrosis factor-α-dependent expression of phosphodiesterase 2: role in endothelial hyperpermeability,” Blood, vol. 105, no. 9, pp. 3569–3576, 2005.
View at: Publisher Site | Google Scholar
M. Abarghaz, S. Biondi, J. Duranton, E. Limanton, C. Mondadori, and P. Wagner, “Preparation of benzo[1,4]diazepin-2-one derivatives as phosphodiesterase PDE2 inhibitors,” Neuro3D, Fr., Application: EP 1548011, p. 46, 2005.
View at: Google Scholar
O. A. H. Reneerkens, K. Rutten, E. Bollen et al., “Inhibition of phoshodiesterase type 2 or type 10 reverses object memory deficits induced by scopolamine or MK-801,” Behavioural Brain Research, vol. 236, no. 1, pp. 16–22, 2013.
View at: Publisher Site | Google Scholar
J. Pandit, M. D. Forman, K. F. Fennell, K. S. Dillman, and F. S. Menniti, “Mechanism for the allosteric regulation of phosphodiesterase 2A deduced from the X-ray structure of a near full-length construct,” Proceedings of the National Academy of Sciences of the United States of America, vol. 106, no. 43, pp. 18225–18230, 2009.
View at: Publisher Site | Google Scholar
M. S. Plummer, J. Cornicelli, H. Roark et al., “Discovery of potent, selective, bioavailable phosphodiesterase 2 (PDE2) inhibitors active in an osteoarthritis pain model. Part I. Transformation of selective pyrazolodiazepinone phosphodiesterase 4 (PDE4) inhibitors into selective PDE2 inhibitors,” Bioorganic & Medicinal Chemistry Letters, vol. 23, no. 11, pp. 3438–3442, 2013.
View at: Publisher Site | Google Scholar
J. Zhu, P. Rehse, and M. He, PDE2 Catalytic Domain/PDE2-Specific Inhibitor Composite Crystal and its Growth Method, American Chemical Society (ACS), Shanghai Medicilon, Shanghai, China, 2014.
T. Banerjee, S. Chaudhuri, M. Moore, S. Ray, P. S. Chatterjee, and P. Roychowdhury, “Synthesis and crystal structures of 5-amino-1-(2-hydroxyethyl)imidazole-4-carboxamide and 5-amino-1-(2-chloroethyl)-4-cyanoimidazole,” Journal of Chemical Crystallography, vol. 29, no. 12, pp. 1281–1286, 1999.
View at: Publisher Site | Google Scholar
B. Alhede, F. P. Clausen, J. Juhl-Christensen, K. K. McCluskey, and H. F. Preikschat, “A simple and efficient synthesis of 9-substituted guanines. Cyclodesulfurization of 1-substituted 5-[(thiocarbamoyl)amino]imidazole-4-carboxamides under aqueous basic conditions,” Journal of Organic Chemistry, vol. 56, no. 6, pp. 2139–2143, 1991.
View at: Publisher Site | Google Scholar
E. Shaw, “Observations on the cyclization of a substituted α-formamidoamidine to aminoimidazolecarboxamide derivatives,” Journal of Organic Chemistry, vol. 30, no. 10, pp. 3371–3373, 1965.
View at: Publisher Site | Google Scholar
U. Niewoehner, E. Bischoff, J. Huetter, E. Perzborn, and H. Schuetz, “Preparation of Purin-6-one derivatives for treatment of cardiovascular and urogenital diseases,” EP 771799, Bayer AG, Leverkusen, Germany, pp.50, 1997.
View at: Google Scholar
X. Y. Zhao, X. Chen, G.-F. Yang, and C.-G. Zhan, “Structural assignment of 6-oxy purine derivatives through computational modeling, synthesis, X-ray diffraction, and spectroscopic analysis,” Journal of Physical Chemistry B, vol. 114, no. 20, pp. 6968–6972, 2010.
View at: Publisher Site | Google Scholar
J. Beltman, D. E. Becker, E. Butt et al., “Characterization of cyclic nucleotide phosphodiesterases with cyclic GMP analogs: topology of the catalytic domains,” Molecular Pharmacology, vol. 47, no. 2, pp. 330–339, 1995.
View at: Google Scholar
X.-j. Zhao, X. Chen, G.-f. Yang, and C.-g. Zhan, “Synthesis of 9-benzyl-2-substituted-purin-6-one derivatives and their bioactivity and molecular docking as potential human phosphodiesterase-2 inhibitors,” Zhongguo Yaowu Huaxue Zazhi, vol. 23, pp. 277–285, 2013.
View at: Google Scholar
R. Islam, N. Ashida, and T. Nagamatsu, “Synthesis and regioselective N- and O-alkylation of 3-alkyl-5-phenyl-3H-[1,2,3]triazolo[4,5-d]pyrimidin-7(6H)-ones and 2-phenyl-9-propyl-9H-purin-6(1H)-one with evaluation of antiviral and antitumor activities,” Tetrahedron, vol. 64, no. 42, pp. 9885–9894, 2008.
View at: Publisher Site | Google Scholar

Copyright

Copyright © 2016 Wei Yuan et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

PDF Download Citation

Download other formats

Order printed copies

Views

1529

Downloads

995

Citations